A practical reference on 研究代号: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-26 and is reviewed periodically as new material appears.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Chenpi – is sun-dried tangerine (mandarin) peel used as a traditional seasoning in Chinese cooking and traditional medicine. Dried cherries Chipotle – a smoked, dried jalapeño pepper. Coconut – can be dried whole or halved. A common product is coconut that has been dried and shredded. Dried cranberry – is made by partially dehydrating fresh cranberries, a process similar to making grapes into raisins.
In his youth Cornaro led a free and immoderate life, as a result by the age of 35 he had many health problems. But by changing his lifestyle he was able to live to 98 (1467–1566). (Though it is possible that he exaggerated his age by about 17 years to give his recommendations more weight.)
Theft of prisoner's possessions by soldiers, dirty, cramped quarters and bad food, prisoners forced into uncomfortable positions for prolonged periods of time, extreme exposure to the elements, and excessive jailings of people based on the paid testimony of individual informants were reported. 55-year-old cafe owner Mahmoud Khodair, who was arrested and held for six months before being released in early March without ever knowing what he was charged with, stated, "It was just like hell", and "Nothing has changed since Saddam. Before, the Mukhabarat [secret police] would take us away, and at least they wouldn't blow down the door. Now, some informant fingers you and gets $100 even if you're innocent." During April 2004 the media started to report on the abuse. The journalist Seymour Hersh (who was awarded the Pulitzer Prize for his disclosure of the Vietnam War tragedy at the hamlet of My Lai) published a series of articles in The New Yorker with photo coverage of U.S. soldiers abusing prisoners in the Abu Ghraib prison on 2004-04-30. In an interview with Dan Rather, the deputy director of operations for the US-led coalition, Brig. Gen. Mark Kimmitt, stated "We're appalled. These are our fellow soldiers. These are the people we work with every day. They represent us. They wear the same uniform as us, and they let their fellow soldiers down.
Sources: en.wikipedia.org
Nutty Professor II: The Klumps is a 2000 American science fiction comedy film directed by Peter Segal and starring Eddie Murphy and Janet Jackson. It is the sequel to the 1996 film The Nutty Professor. In contrast to the previous film, subplots centered on the parents of protagonist Sherman Klump occupy a substantial part of the film. Nutty Professor II: The Klumps was released by Universal Pictures on July 28, 2000. Unlike its predecessor, the film received generally negative reviews and grossed $166.3 million.
Quinteiro, Javier; Baibai, Tarik; Oukhattar, Laila; Soukri, Abdelaziz; Seixas, Pablo; Rey-Méndez, Manuel (2011). "Multiple paternity in the common octopus Octopus vulgaris (Cuvier, 1797), as revealed by microsatellite DNA analysis" (PDF). Molluscan Research. 31 (1): 15–20. Bibcode:2011MollR..311.1.2Q. CiteSeerX 10.1.1.363.8342. doi:10.11646/mr.31.1.2. {{cite journal}}: Cite uses deprecated parameter |citeseerx= (help) "CephBase: Common octopus". Archived from the original on 17 August 2005. Photos of Common octopus in the Sealife Collection
Fischer (born 1979/1980), American chemist notable for work on the WE-CAN project and on peroxyacetyl nitrate Ernst Gottfried Fischer (1754–1831), German chemist who proposed a system of equivalents based on sulfuric acid equal to 1000 Ernst Otto Fischer (1918–2007), German chemist, 1973 Nobel Prize in Chemistry for pioneering work on organometallic chemistry Franz Joseph Emil Fischer (1877–1947), German chemist, co-discovered the Fischer–Tropsch process Hans Fischer (1881–1945), German organic chemist, 1930 Nobel Prize in Chemistry for research on the constitution of haemin and chlorophyll Nellie Ivy Fisher (1907–1995), London-born industrial chemist known for photographic chemistry Wilhelm Rudolph Fittig (1835–1910), German chemist, co-discovered Wurtz–Fittig reaction
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。